Jounce Therapeutics, Inc.
(NASDAQ : JNCE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.37%242.401.5%$875.87m
MRNAModerna, Inc. 5.12%150.170.0%$811.88m
VRTXVertex Pharmaceuticals, Inc. 0.28%282.591.9%$481.19m
GILDGilead Sciences, Inc. -0.32%61.611.0%$473.86m
REGNRegeneron Pharmaceuticals, Inc. -0.42%588.642.6%$469.68m
NVAXNovavax, Inc. 10.77%56.9775.7%$441.45m
ILMNIllumina, Inc. 1.55%187.223.3%$341.07m
SNSSSunesis Pharmaceuticals, Inc. -1.03%3.840.7%$268.43m
BIIBBiogen, Inc. 1.24%206.461.8%$241.01m
BNTXBioNTech SE 4.15%155.280.0%$194.91m
CRSPCRISPR Therapeutics AG 3.36%62.810.6%$165.46m
BMRNBioMarin Pharmaceutical, Inc. 0.70%83.454.2%$116.99m
EXASEXACT Sciences Corp. 2.45%40.3617.7%$93.17m
IOVAIovance Biotherapeutics, Inc. 2.94%11.370.0%$90.74m
TECHBio-Techne Corp. 0.41%348.054.5%$89.98m

Company Profile

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.